Faculty Profiles - MITSUMA, Ayako

Papers - MITSUMA, Ayako

Division display 21 - 40 of about 63 ／ All the affair displays >>

Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device

Matsuoka, A; Mitsuma, A; Maeda, O; Kajiyama, H; Kiyoi, H; Kodera, Y; Nagino, M; Goto, H; Ando, Y

CANCER SCIENCE Vol. 107 ( 10 ) page： 1453 - 1457 2016.10

Language：English Publisher：Wiley

<jats:p>Chemotherapy‐induced peripheral neurotoxicity (<jats:styled-content style="fixed-case">CIPN</jats:styled-content>) seriously impairs patients’ quality of life cumulatively and dose‐dependently. Because assessment of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> usually depends on patients’ subjective evaluation of symptoms, objective and quantitative measures are needed. We evaluated a point‐of‐care nerve conduction device (<jats:styled-content style="fixed-case">POCD</jats:styled-content>), previously validated for the assessment of diabetic peripheral neuropathy. Sensory nerve action potential (<jats:styled-content style="fixed-case">SNAP</jats:styled-content>) amplitude and sensory nerve conduction velocity (<jats:styled-content style="fixed-case">SNCV</jats:styled-content>) of the sural nerve were measured using a portable, automated <jats:styled-content style="fixed-case">POCD</jats:styled-content> (DPNCheck; NeuroMetrix Inc., Waltham, MA, USA) in patients with a clinical diagnosis of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> of grade 1 or higher. We compared <jats:styled-content style="fixed-case">SNAP</jats:styled-content> and <jats:styled-content style="fixed-case">SNCV</jats:styled-content> among patients with different grades of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> according to the Common Terminology Criteria for Adverse Events. A total of 50 patients (22 men, 28 women; median age, 64 years; grade 1/2/3, 21/18/11) were evaluated. Anticancer drugs responsible for <jats:styled-content style="fixed-case">CIPN</jats:styled-content> were cisplatin in five patients, oxaliplatin in 15, carboplatin in 5, paclitaxel in 16, docetaxel in 14, nab‐paclitaxel in 7, vincristine in 6, and bortezomib in 3. Unadjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> was 8.45 ± 3.67 μV (mean ± SD) in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 5.42 ± 2.68 μV with grade 2, and 2.45 ± 1.52 μV with grade 3. Unadjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> was 49.71 ± 4.77 m/s in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 48.78 ± 6.33 m/s with grade 2, and 44.14 ± 7.31 m/s with grade 3. The adjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> after controlling for age significantly differed between each <jats:styled-content style="fixed-case">CTCAE</jats:styled-content> grade (<jats:italic>P</jats:italic> < 0.001, <jats:sc>ancova</jats:sc>). The adjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> after controlling for age and height also differed significantly (<jats:italic>P</jats:italic> = 0.027). Differences in the severity of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> could be detected objectively and quantitatively using this <jats:styled-content style="fixed-case">POCD</jats:styled-content>.</jats:p>

DOI： 10.1111/cas.13010

特集:癌化学療法に伴う神経障害性疼痛-最近の研究動向臨床現場からの情報発信:「オキサリプラチンによる末梢神経障害の遺伝的背景」

満間綾子, 安藤雄一

日本薬理学会誌 Vol. vol.141 No.2 page： 62 - 65 2013

特集PK-PDとPGxの最前線「がん分子標的薬のPK-PDとPGx」

満間綾子, 安藤雄一

月刊薬事 Vol. vol.52 No.4 page： 39 - 46 2010

Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi

CANCER SCIENCE Vol. 112 ( 2 ) page： 725 - 733 2021.2

Chemotherapy for biliary tract cancer: real-world experience in a single institute

Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 725 - 733 2020.11

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 631 - 644 2020.11

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro

INTERNATIONAL JOURNAL OF CANCER Vol. 146 ( 12 ) page： 3504 - 3515 2020.6

Detection of bacteria in blood circulation in patients receiving cancer chemotherapy.

Ota A, Morita S, Matsuoka A, Shimokata T, Maeda O, Mitsuma A, Yagi T, Asahara T, Ando Y

International journal of clinical oncology Vol. 25 ( 1 ) page： 210 - 215 2020.1

A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

Matsuoka A., Mitsuma A., Maeda O., Tsunoda N., Kikumori T., Ando Y.

ANNALS OF ONCOLOGY Vol. 30 2019.10

Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

Ando Yuichi, Doi Toshihiko, Mitsuma Ayako, Mizutani Takefumi, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Naito Yoichi, Matsubara Nobuaki, Ishihara Kae, Tajima Takeshi, Tokushige Kota, Cameron Scott, Minami Hironobu

ANNALS OF ONCOLOGY Vol. 29 page： . 2018.10

Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi

ANNALS OF ONCOLOGY Vol. 29 page： . 2018.10

A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

Matsuoka A., Maeda O., Mitsuma A., Uehara K., Nakayama G., Nagino M., Kodera Y., Ando Y.

ANNALS OF ONCOLOGY Vol. 29 page： . 2018.10

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, Ishigure Kiyoshi, Yokoyama Hiroyuki, Matsui Takanori, Nakayama Hiroshi, Nakata Kazuhiko, Ishiyama Akiharu, Asada Takahiro, Umeda Shinichi, Ezaka Kazuhiro, Hattori Norifumi, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Kanda Mitsuro, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

ONCOLOGIST Vol. 23 ( 8 ) page： 919 - 927 2018.8

Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

ANNALS OF ONCOLOGY Vol. 28 page： 69-69 2017.11

Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

Molecular and clinical oncology Vol. 7 ( 3 ) page： 510 2017.9

Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

BREAST CANCER Vol. 24 ( 2 ) page： 312 - 318 2017.3

Salient features and outline of the joint Japanese guidelines for safe handling of cancer chemotherapy drugs

Kanda Kiyoko, Hirai Kazue, Iino Keiko, Nomura Hisanaga, Yasui Hisateru, Kano Taro, Ichikawa Chisato, Hiura Sumiko, Morita Tomoko, Mitsuma Ayako, Komatsu Hiroko

ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING Vol. 4 ( 4 ) page： 304 - 312 2017

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review

Yamamoto Eiko, Niimi Kaoru, Fujikake Kayo, Nishida Tetsuya, Murata Makoto, Mitsuma Ayako, Ando Yuichi, Kikkawa Fumitaka

MOLECULAR AND CLINICAL ONCOLOGY Vol. 5 ( 5 ) page： 660 - 664 2016.11

Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer

Sugishita Mihoko, Imai Tsuneo, Kikumori Toyone, Mitsuma Ayako, Shimokata Tomoya, Shibata Takashi, Morita Sachi, Inada-Inoue Megumi, Sawaki Masataka, Hasegawa Yoshinori, Ando Yuichi

BREAST CANCER Vol. 23 ( 2 ) page： 195 - 201 2016.3

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction

Shibata Takashi, Ebata Tomoki, Fujita Ken-ichi, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Sasaki Yasutsuna, Nagino Masato, Ando Yuichi

CANCER SCIENCE Vol. 107 ( 2 ) page： 168 - 172 2016.2

　 PREV - NEXT 　

<MITSUMA, Ayako>

Papers - MITSUMA, Ayako